3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
11
Fluorouracil
10
pembrolizumab
9
Cisplatin
9
Radiotherapy
7
Carboplatin
6
Esophagectomy
5
Nivolumab
4
Drug Therapy
4
Radiotherapy, Intensity-Modulated
3
Leucovorin
3
Chemoradiotherapy
3
Cetuximab
3
Capecitabine
3
durvalumab
2
atezolizumab
2
Oxaliplatin
2
Ipilimumab
2
spartalizumab
1
sintilimab
1
selinexor
1
regorafenib
1
prexasertib
1
osimertinib
1
niraparib
1
nilotinib
1
nedaplatin
1
nanocis
1
fludarabine
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
nanocis
×
Gastrointestinal
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled